Related Experiment Video
Updated: Jul 29, 2026

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
Genetic factors in aminoglycoside toxicity
1Cedars-Sinai Medical Center, Department of Pediatrics, Suite 1165WT, 8700 Beverly Blvd., Los Angeles, CA 90048, USA. nathan.fischel@cshs.org
Abstract:
Ototoxicity is the major irreversible toxicity of aminoglycosides, and it occurs both in a dose-dependent and idiosyncratic fashion. The idiosyncratic pathway is presumably due to genetic predispositions, and an inherited mutation in the mitochondrial 12S ribosomal RNA gene that predisposes carriers to aminoglycoside ototoxicity was identified in 1993. Up to a third of patients with aminoglycoside ototoxicity carry this mutation. Two other mutations in the same mitochondrial gene affect a small minority of additional patients. Thus, the prevention of aminoglycoside-induced ototoxicity through family history and molecular diagnosis is possible in many cases. It is the challenge of genomic medicine to translate this more than a decade-old knowledge into clinical practice.
Related Concept Videos
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Drug Toxicity: Risk factors
Drug Toxicity: Dose-Dependent Reactions
Drug toxicity: Idiosyncratic Reactions
Inhibitors of Bacterial Protein Synthesis

